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from a fatal disease to amanageable condition. Improvements in insulin
formulation and development of devices for patients to deliver insulin
andmeasure blood sugar have combined to produce one of themost re-
markable success stories in drug and device development in the 20th
century. Life expectancy in T1D has increased dramatically and many
patients, particularly those who are able to sustain the demanding and
costly self-care regimen that good glucose control requires, live long
and healthy lives. But T1D remains a very serious chronic illness – com-
monly beginning in childhood – a disease that imposes a huge burden
on the patients themselves, as well as their families and on society as
a whole. Furthermore, despite advances in insulin delivery and glucose
monitoring, it is extremely challenging to achieve long-term glucose
control, resulting in signiﬁcant risks for acute and chronic complica-
tions. In addition, the incidence of T1D continues to increase, especially
in the very young. In order to reduce the human suffering related to T1D
aswell as the large ﬁnancial costs of T1D and its complications, efforts at
curing T1D in thosewhohave already beendiagnosed, and preventing it
for the future, are of paramount importance.
A cure for T1D will likely involve the use of replacement beta cells,
the insulin-producing cells of the pancreas that are lost in the autoim-
mune assault that is a hallmark of the disease. Beta cells both produce
insulin and sense glucose and calibrate the delivery of appropriate
amounts of insulin without causing hypoglycemia or permitting hyper-
glycemia, a remarkable process occurring reliably – and automatically –
throughout a lifetime in a person without diabetes.
Cadaveric beta cells are already in clinical use. Islet cell transplanta-
tion or pancreatic transplantation can, in principle, cure T1D— although
long-term success rates with current procedures are not optimal. More
than 1000 pancreas transplants are performed each year in the USA,
most for T1D (Gruessner, 2011). Worldwide, fewer than 100 islet trans-
plants are performed yearly (Barton et al., 2012). Life-long immunosup-
pressive therapy is required to prevent the recurrence of T1D from
autoimmunity and to prevent allo-rejection. The need for immunosup-
pression, along with the scarcity of donor islets, restricts current use of
cadaveric transplantation to only a small subset of T1D patients, such
as those who are receiving immunosuppression for another indication,
such as a kidney transplant.⁎ Corresponding author at: Naomi Berrie Diabetes Center, College of Physicians and
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2352-3964/© 2014 Published by Elsevier B.V.Another potential source of beta cells that could be used in diabetes
treatment are embryonic stem cells. Baetge and colleagues reported
preliminary success at beta cell differentiation — they showed that ex-
posing embryonic stem cells to a series of molecules participating in
pancreatic development gave rise to insulin-producing cells in vitro
(D'Amour et al., 2006). These cells were not functionally mature: they
co-expressed glucagon in addition to insulin, and failed to increase insu-
lin secretion in response to high glucose ambient levels. But remarkably,
when these immature cells were transplanted into mice, mature beta
cells formed— cells that could maintain normal glucose levels after ab-
lation of the mouse's intrinsic pancreatic beta cells (Kroon et al., 2008).
These pioneering studies are now the basis for an ongoing clinical trial
that will determine whether immature stem cell-derived pancreatic
cells will yield insulin-secreting beta cells when transplanted into
human subjects with T1D.
The recent ﬁnding by Douglas Melton and colleagues, as well as
Rezania and colleagues constitutes further progress and suggests that
in vitro generation of more mature beta cells from stem cells is possible
in vitro before transplantation. Using a complex, multi-stage protocol,
beta cells that are very similar to the cells in the human pancreas have
now been generated (Pagliuca et al., 2014; Rezania et al., 2014). Unlike
earlier versions, these beta cells express insulin, but not other pancreatic
hormones, respond to repeated glucose stimulation with increased in-
sulin secretion, and containmature insulin granules by electronmicros-
copy. And diabetic mice transplanted with these cells show normal
blood glucose levels within several weeks, instead of the months re-
quired for functional maturation of beta cells in the earlier experiments.
Differentiation from pluripotent stem cells can be performed in large
volumes of suspended cells, allowing the production of amounts of
cells (about half to a billion cells per transplant) that would be required
for the treatment of human subjects. This work helps address one criti-
cal obstacle in the use of beta cells for cell replacement therapy for dia-
betes in the future, the availability of sufﬁcient numbers of mature beta
cells for transplantation. This report was met by understandable excite-
ment by many in the diabetes ﬁeld, including T1D patients and their
families living every day with this challenging condition.
Themost immediate use of stemcell-derived beta cells is in research.
These cells are useful for investigation into the mechanisms of beta cell
failure, as demonstrated in studies of monogenic diabetes (Shang et al.,
2013). These proof-of-principle studies showed that these stem cell-
derived beta cells show molecular phenotypes that recapitulate those
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studies of T1D in humanized mouse models of autoimmunity. Such
mice could prove critical for the testing of therapies to prevent beta
cell destruction.
Use of cell based therapies for T1Dwill still need to overcome or by-
pass autoimmunity. Though we can likely prevent allo-rejection by uti-
lizing patient-speciﬁc stem cell-derived beta cells that are generated
from the T1D patient receiving the transplant (Maehr et al., 2009;
Yamada et al., 2014), auto-immunity and T1D would probably recur
by virtue of ongoing immune assault on molecular components of the
beta cell (Tyden et al., 1996). The need for immunosuppressive drugs
would again limit beta cell transplantation, even with stem cell-
derived beta cells, to a small subset of patients, until the autoimmunity
can be addressed. The use of encapsulation – an immune-protective
membrane encapsulating the transplanted beta cells – is one possible
approach under study. The durability of such transplants is unknown.
The development of personalized cell replacement therapy for dia-
betes is a formidable challenge. The complexity is daunting and success
will require effective collaboration between experts in ﬁelds as diverse
as tissue engineering, immunology, stem cell research and clinical
care. Experimental treatments will need to be continuously evaluated
against the efﬁcacy and safety of current clinical care, a high standard
to match. As unsolved questions regarding safety and efﬁcacy of cell-
based treatments for T1D are related to the immune system, beta cell re-
placement for patients with non-immune mediated diabetes, such as
those with maturity onset diabetes of the young (MODY) or cysticﬁbrosis, may provide clinical settings in which experience with these
strategies can be gained. Though success is uncertain, it is a goal
worth pursuing,with potentially transformative effects onmedicine, re-
placing life-long diabetes disease management, with a cure using the
patient's own cells.
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